Cargando…

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

INTRODUCTION: Novel adjuvant therapies are needed to prevent metastatic relapses in HER2-expressing breast cancer. Here, we tested whether trastuzumab-selected single-chain Fv (scFv) could be used to develop an anti-idiotype-based vaccine to inhibit growth of HER2-positive tumor cells in vitro and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ladjemi, Maha Z, Chardes, Thierry, Corgnac, Stephanie, Garambois, Veronique, Morisseau, Sebastien, Robert, Bruno, Bascoul-Mollevi, Caroline, Ait Arsa, Imade, Jacot, William, Pouget, Jean-Pierre, Pelegrin, Andre, Navarro-Teulon, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109586/ https://www.ncbi.nlm.nih.gov/pubmed/21294885 http://dx.doi.org/10.1186/bcr2826

Ejemplares similares

Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer
por: Park, Sunju, et al.
Publicado: (2017)

Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice
por: Coelho, M, et al.
Publicado: (2004)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using (2) (1) (2)Pb
por: Boudousq, Vincent, et al.
Publicado: (2013)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021)

The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation
por: Le Clorennec, Christophe, et al.
Publicado: (2016)

Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells
por: Chauvin, Maëva, et al.
Publicado: (2021)

Co-Expression of Chaperones for Improvement of Soluble Expression and Purification of An Anti-HER2 scFv in Escherichia Coli
por: Estabragh, Amir Mirzapour, et al.
Publicado: (2022)

Quantification of HER Expression and Dimerization in Patients’ Tumor Samples Using Time-Resolved Förster Resonance Energy Transfer
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2012)

Integrated in Silico and Experimental Approach towards the Design of a Novel Recombinant Protein Containing an Anti-HER2 scFv
por: Santos, Joana, et al.
Publicado: (2021)

Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo
por: Zhang, Haiqiang, et al.
Publicado: (2022)

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
por: Alric, Christophe, et al.
Publicado: (2018)

Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival
por: Chauvin, Maëva, et al.
Publicado: (2021)

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
por: Thomas, GaëLle, et al.
Publicado: (2014)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer
por: Sun, Jiangang, et al.
Publicado: (2022)

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells
por: Le Clorennec, Christophe, et al.
Publicado: (2019)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

High scFv-receptor affinity does not enhance the antitumor activity of HER2 retargeted measles virus
por: Suksanpaisan, Lukkana, et al.
Publicado: (2014)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
por: Assenat, Eric, et al.
Publicado: (2015)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements
por: Ladjemi, Maha Z.
Publicado: (2012)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
por: Gómez-Martin, Carlos, et al.
Publicado: (2012)

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
por: Strasser-Weippl, Kathrin, et al.
Publicado: (2015)

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
por: Cheng, Jackie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6oc8f6nhqan9e0vb4grba9mi4p